A new synthetic DNA-powered “smart” cancer treatment has been developed by researchers at the University of Geneva (UNIGE), which enables drugs to target harmful cancer cells with precision, avoiding damage to healthy tissue.
Revealed in a new paper published in Nature Biotechnology, the discovery of such a workaround has long eluded cancer researchers, where treatment can often be almost as destructive as the disease itself. Beyond cancer treatment, the UNIGE team says that their discovery can be applied to create smart medicines for a variety of challenging ailments and is highly effective against drug-resistant illnesses.
Cancer Treatment
Chemotherapy is one of the most commonly used and well-known cancer treatments. Unfortunately, it is as well known for its side effects as its effectiveness: the radiation that kills cancer cells also attacks healthy cells, leading to fatigue, nausea, vomiting, hair loss, and other symptoms. Undergoing the treatment puts cancer sufferers through a difficult ordeal while they are coping with a potentially life-threatening health crisis.
One advancement in more precisely targeting cancers is a type of biological “missile” known as an antibody drug conjugate (ADC). These ADCs combine a monoclonal antibody with a cell-killing payload, delivering the payload directly to the target site. However, while these can be useful, they are imperfect solutions due to their limited payload capacity and difficulty penetrating dense tumor tissue.
The new synthetic DNA-based technology from UNIGE relies on DNA’s small components to more effectively cross cell membranes while carrying more drug molecules than an ADC.
Targeting Cancer Drugs
The UNIGE system combines multiple DNA strands, each carrying its own distinctive component, almost like a cancer-fighting octopus. These specialized components include a cytotoxic drug, meaning that it kills cells, and two separate cancer-targeting binders. Using two different markers enables more secure identification of cancer cells.
Once those binders locate and attach to cancer markers, the system begins to assemble components at the site of the tumor. Doing so allows for higher drug concentrations, which can be amplified on demand—until that final assembly, the drug remains inert.
The researchers conducted laboratory studies to evaluate the effectiveness of their new system, finding that it could successfully differentiate cancer cells from healthy cells using combinations of surface proteins. As a bonus for dealing with drug-resistant cancers, their system allowed for combining multiple therapeutics.
Evolving Cancer Treatment
“This could mark an important step forward in the evolution of medicine, with the introduction of a self-operating drug system,” said co-author Nicolas Winssinger, full professor in the Department of Organic Chemistry of the School of Chemistry and Biochemistry, Faculty of Science, UNIGE.
“Until now, computers and AI have helped us design new drugs,” Winssinger said. “What’s new here is that the drug itself can, in a simple way, ‘compute’ and respond intelligently to biological signals.”
The “smart” system is based on Boolean operators, the logical concepts of “and,” “or,” and “not,” which underpin how data scientists parse databases and how search engines operate. Only with a successful “and” operation, when both biomarkers are detected, does the system activate and assemble the drug components.
The researchers say that in the future, even more complex logical operators could be added to such a system. This would allow scientists to program highly intelligent drugs tailored to each patient’s unique body chemistry, maximizing efficacy while minimizing side effects.
The paper, “DNA–Drug Conjugates Enable Logic-Gated Drug Delivery Amplified by Hybridization Chain Reactions,” appeared in Nature Biotechnology on March 27, 2026.
Ryan Whalen covers science and technology for The Debrief. He holds an MA in History and a Master of Library and Information Science with a certificate in Data Science. He can be contacted at ryan@thedebrief.org, and follow him on Twitter @mdntwvlf.